BRPI0412809A - compostos de sulfonildihidrobenzimidazolona como ligantes a 5-hidróxitriptamina-6 - Google Patents
compostos de sulfonildihidrobenzimidazolona como ligantes a 5-hidróxitriptamina-6Info
- Publication number
- BRPI0412809A BRPI0412809A BRPI0412809-5A BRPI0412809A BRPI0412809A BR PI0412809 A BRPI0412809 A BR PI0412809A BR PI0412809 A BRPI0412809 A BR PI0412809A BR PI0412809 A BRPI0412809 A BR PI0412809A
- Authority
- BR
- Brazil
- Prior art keywords
- binders
- compounds
- dihydrobenzimidazolone
- hydroxytryptamine
- sulfonyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Nutrition Science (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
"COMPOSTOS DE SULFONILDIHIDROBENZIMIDAZOLONA COMO LIGANTES A 5-HIDRóXITRIPTAMINA-6". A presente invenção proporciona um composto da fórmula I e o uso do mesmo no tratamento terapêutico de um distúrbio no sistema nervoso central relacionado a ou afetado pelo receptor 5-HT6.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48941703P | 2003-07-23 | 2003-07-23 | |
PCT/US2004/023243 WO2005009996A1 (en) | 2003-07-23 | 2004-07-19 | Sulfonyldihydro- benzimidazolone compounds as 5-hydroxytryptamine-6 ligands |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0412809A true BRPI0412809A (pt) | 2006-09-26 |
Family
ID=34102869
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0412809-5A BRPI0412809A (pt) | 2003-07-23 | 2004-07-19 | compostos de sulfonildihidrobenzimidazolona como ligantes a 5-hidróxitriptamina-6 |
Country Status (9)
Country | Link |
---|---|
US (1) | US7544701B2 (pt) |
EP (1) | EP1654258A1 (pt) |
JP (1) | JP2006528186A (pt) |
CN (1) | CN1823062A (pt) |
AU (1) | AU2004259739A1 (pt) |
BR (1) | BRPI0412809A (pt) |
CA (1) | CA2532071A1 (pt) |
MX (1) | MXPA06000701A (pt) |
WO (1) | WO2005009996A1 (pt) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200401641A (en) * | 2002-07-18 | 2004-02-01 | Wyeth Corp | 1-Heterocyclylalkyl-3-sulfonylindole or-indazole derivatives as 5-hydroxytryptamine-6 ligands |
JP2009501184A (ja) * | 2005-07-13 | 2009-01-15 | エフ.ホフマン−ラ ロシュ アーゲー | 5−ht6、5−ht24としてのベンゾイミダゾール誘導体 |
JP5209479B2 (ja) * | 2005-09-30 | 2013-06-12 | グラクソ グループ リミテッド | M1受容体にて活性を有するベンゾイミダゾロン類 |
ES2391107T3 (es) * | 2005-09-30 | 2012-11-21 | Glaxo Group Limited | Compuestos que tienen actividad en el receptor M1 y sus usos en medicina |
AU2006296369B2 (en) * | 2005-09-30 | 2012-12-20 | Glaxo Group Limited | Compounds which have activity at M1 receptor and their uses in medicine |
TWI403508B (zh) | 2006-08-26 | 2013-08-01 | Abbott Gmbh & Co Kg | 經取代苯并咪唑酮衍生物、包含其之醫藥品及其用途 |
US20080171779A1 (en) * | 2007-01-16 | 2008-07-17 | Solvay Pharmaceuticals B.V. | Use of 5-ht6 antagonists to prevent relapse into addiction |
GB0718415D0 (en) * | 2007-09-20 | 2007-10-31 | Glaxo Group Ltd | Compounds |
EP2053052A1 (en) * | 2007-10-23 | 2009-04-29 | Laboratorios del Dr. Esteve S.A. | Process for the preparation of 6-substituted imidazo[2,1-b]thiazole-5-sulfonyl halide |
US8846743B2 (en) | 2010-08-13 | 2014-09-30 | Abbott Laboratories | Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy |
US8877794B2 (en) | 2010-08-13 | 2014-11-04 | Abbott Laboratories | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy |
US9309200B2 (en) | 2011-05-12 | 2016-04-12 | AbbVie Deutschland GmbH & Co. KG | Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy |
US9365512B2 (en) | 2012-02-13 | 2016-06-14 | AbbVie Deutschland GmbH & Co. KG | Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy |
AU2014230122A1 (en) * | 2013-03-15 | 2015-08-06 | AbbVie Deutschland GmbH & Co. KG | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy |
US9650334B2 (en) | 2013-03-15 | 2017-05-16 | Abbvie Inc. | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy |
US9656955B2 (en) | 2013-03-15 | 2017-05-23 | Abbvie Inc. | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy |
CN103232397B (zh) * | 2013-04-28 | 2016-04-20 | 江苏双乐化工颜料有限公司 | 5-氨基-n-取代苯并咪唑酮的合成方法 |
JP2016537323A (ja) | 2013-10-17 | 2016-12-01 | アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー | アミノクロマン誘導体、アミノチオクロマン誘導体およびアミノ−1,2,3,4−テトラヒドロキノリン誘導体、これらを含有する医薬組成物、および治療におけるこれらの使用 |
EP3057958B1 (en) | 2013-10-17 | 2019-05-01 | AbbVie Deutschland GmbH & Co. KG | Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5288749A (en) | 1991-12-20 | 1994-02-22 | Abbott Laboratories | Tertiary and secondary amines as alpha-2 antagonists and serotonin uptake inhibitors |
FR2708608B1 (fr) | 1993-07-30 | 1995-10-27 | Sanofi Sa | Dérivés de N-sulfonylbenzimidazolone, leur préparation, les compositions pharmaceutiques en contenant. |
EP0778277B1 (en) | 1995-12-08 | 2003-06-25 | Pfizer Inc. | Substituted heterocyclic derivatives as CRF antagonists |
US6686374B1 (en) | 1999-08-12 | 2004-02-03 | Nps Allelix Corp. | Azaindoles having serotonin receptor affinity |
CA2382247C (en) * | 1999-08-12 | 2010-09-28 | Nps Allelix Corp. | Azaindoles having serotonin receptor affinity |
JP2001058991A (ja) * | 1999-08-20 | 2001-03-06 | Banyu Pharmaceut Co Ltd | スルホンアミド誘導体 |
EP1221443B1 (en) | 1999-10-13 | 2004-09-01 | Banyu Pharmaceutical Co., Ltd. | Substituted imidazolidinone derivatives |
CA2470863C (en) | 2001-12-20 | 2012-05-15 | Wyeth | Indolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands |
-
2004
- 2004-07-19 JP JP2006521177A patent/JP2006528186A/ja active Pending
- 2004-07-19 CN CNA2004800202493A patent/CN1823062A/zh active Pending
- 2004-07-19 MX MXPA06000701A patent/MXPA06000701A/es unknown
- 2004-07-19 WO PCT/US2004/023243 patent/WO2005009996A1/en active Application Filing
- 2004-07-19 EP EP04778650A patent/EP1654258A1/en not_active Withdrawn
- 2004-07-19 CA CA002532071A patent/CA2532071A1/en not_active Abandoned
- 2004-07-19 AU AU2004259739A patent/AU2004259739A1/en not_active Abandoned
- 2004-07-19 BR BRPI0412809-5A patent/BRPI0412809A/pt not_active Application Discontinuation
- 2004-07-22 US US10/897,153 patent/US7544701B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO2005009996A1 (en) | 2005-02-03 |
CA2532071A1 (en) | 2005-02-03 |
EP1654258A1 (en) | 2006-05-10 |
US7544701B2 (en) | 2009-06-09 |
US20050020575A1 (en) | 2005-01-27 |
JP2006528186A (ja) | 2006-12-14 |
CN1823062A (zh) | 2006-08-23 |
MXPA06000701A (es) | 2006-04-11 |
AU2004259739A1 (en) | 2005-02-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0312758A (pt) | Derivados de 1-heterociclilalquil-3-sulfonilazaindol ou -azaindazol como ligantes da 5-hidroxitriptamina-6 | |
BR0312759A (pt) | Derivados de 1-heterociclilalquil-3-sulfonilindol ou -indazol como ligantes de 5-hidroxitriptamina-6 | |
BR0206633A (pt) | Derivados de 1-aril- ou 1-arilsulfonilbenzazol como ligandos de 5-hidroxitriptamina-6 | |
BRPI0412809A (pt) | compostos de sulfonildihidrobenzimidazolona como ligantes a 5-hidróxitriptamina-6 | |
BR0209056A (pt) | Derivados de heterociclilóxi-, -tióxi- e -aminobenzazol como ligantes de 5-hidroxitriptamina-6 | |
BR0215151A (pt) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
BR0116323A (pt) | Compostos de heterociclilindazol e -azaindazol como ligandos de 5-hidroxitriptamina-6 | |
BR0311436A (pt) | Derivados de 1-(aminoalquil)-3-sulfoni-lindol e -indazol como ligandos da 5-hidroxitriptamina-6 | |
BR0115102A (pt) | 1-aril- ou 1-alquilsulfonil-heterociclilbenzazóis como ligantes 5-hidroxitriptamina-6 | |
BR0311591A (pt) | 1-(aminoalquil)-2-sulfonilazindóis como ligandos de 5-hidroxitriptamina-6 | |
BR0215222A (pt) | Derivados de indolilalquilamina como ligantes de 5-hidroxitriptamina-6 | |
ECSP055964A (es) | Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6 | |
BRPI0418099A (pt) | compostos, composição farmacêutica, e uso de um composto | |
EA200501332A1 (ru) | Производные пиримидин-4-она и их применение в качестве модуляторов киназы p38 | |
BR0116481A (pt) | Compostos de heterociclilalquilindol ou azaindol como ligandos de 5-hidroxitriptamina-6 | |
ECSP045229A (es) | Piridinonas sustituidas como moduladores de la p38 map quinasa | |
BR0213094A (pt) | Derivados de cromano como ligandos de 5-hidroxi-triptamina-6 | |
PA8609201A1 (es) | Piridinonas sustituidas | |
UY28157A1 (es) | Miméticos de glucocorticoides métodos para su elaboración composiciones farmacéuticas y sus usos | |
EA200870360A1 (ru) | Бензимидазолы, обладающие активностью в отношении рецепторов м1, и их применение в медицине | |
BR0209047A (pt) | Derivados de heterociclilalcóxi-, -alquiltio- e -alquilaminobenzazol como ligantes de 5-hidroxitriptamina-6 | |
CR9650A (es) | Derivados de tienopirimidina y tienopiridina como inhibidores de tirosina cinasa 3 tipo fms | |
EA200600071A1 (ru) | Производные n-фенилпиперазина и способы профилактики или лечения заболеваний, связанных с 5ht-рецептором | |
BRPI0416371A (pt) | composto de sulfoniltetrahidro-3h-benzo(e)indol-8-amina como ligantes de 5-hidroxitriptamina-6 | |
DE60221425D1 (de) | Substituierte tetrazyklische pyprolochinolonderivate als phosphodiesterase-inhibitoren |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |